Diet and Lifestyle for Constipation on Wegovy (semaglutide 2.4 mg): What Actually Works

What the Wegovy label reports

The constipation figure in the Wegovy label comes from pooled placebo-controlled trials of the 2.4 mg weekly injection in adults with obesity or overweight. Constipation was reported by 24% on Wegovy and 11% on placebo [1]. Any GI reaction occurred in 73% versus 47%, and severe GI adverse reactions in 4.1% versus 0.9% [1]. These are adverse-event counts, not results of a diet trial.

The label also says semaglutide delays gastric emptying [1]. It does not say semaglutide causes gastroparesis; it says Wegovy is not recommended in patients with severe gastroparesis [1]. After marketing, the label lists ileus, intestinal obstruction and severe constipation including fecal impaction, and says their frequency cannot be estimated from voluntary reports [1].

What the label says about diet and lifestyle

The label's adverse-reaction tables record how often constipation occurred. They do not report fiber targets, fluid targets, meal timing, exercise or supplements as treatments for it, so the label offers no diet or lifestyle result to quote for Wegovy constipation [1].

The wider GI picture

The label also gives the drug's broader GI profile: nausea 44% versus 16%, diarrhea 30% versus 16%, vomiting 24% versus 6% and abdominal pain 20% versus 10% on Wegovy 2.4 mg versus placebo [1].